Okada Yoshinori, Zuo Xiao-Jing, Toyoda Mieko, Marchevsky Alberto, Matloff Jack M, Oishi Hisashi, Kondo Takashi, Jordan Stanley C
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan.
Transpl Immunol. 2006 Aug;16(2):95-8. doi: 10.1016/j.trim.2006.03.012. Epub 2006 Apr 19.
The ability to express genes with potential immunoregulatory capacity could reduce allograft rejection (AR). We examined the feasibility of transferring the viral interleukin-10 (vIL-10) gene into rat lungs by intra-bronchial instillation and the subsequent effects of delivered vIL-10 on acute lung AR.
First, the adenoviral beta-galactosidase vector (adv-beta-gal) particles were instilled into the airway of the rat lung and protein synthesis of beta-gal was examined by histochemical staining. Next, the ability of the adenoviral vIL-10 vector (adv-vIL-10) transfection to modify AR was examined in a highly histoincompatible rat lung transplant model (BN-->Lew). Donor left lungs were transfected with 3 x 10(8) pfu/0.3 mL of adv-vIL-10 (vIL-10 group) or adv-beta-gal (control group) 3 days before transplantation. On day 6 post-transplant, lung allografts were harvested and AR was graded histologically (stage 0-4). Several pathological categories of inflammation (perivascular, peribronchial, or peribronchiolar mononuclear infiltrates, edema, vasculitis, intraalveolar hemorrhage, and necrosis) were also examined and scored on a scale of 0-4 as previously described.
A successful transgene protein synthesis by adv-beta-gal in alveolar epithelial cells and alveolar macrophages was confirmed by histochemical staining with X-gal. The vIL-10 group showed a trend toward an improved stage of AR (3.75 +/- 0.5 vs. 4.0 +/- 0), and also a decreased pathological scores for edema (3.5 +/- 0.6 vs. 4.0 +/- 0), intraalveolar hemorrhage (2.3 +/- 1.0 vs. 2.5 +/- 0.6) and necrosis (1.5 +/- 0.5 vs. 1.75 +/- 1.3) compared with the control group, however, the differences in any pathological scores between the two groups did not reach a statistical significance.
表达具有潜在免疫调节能力基因的能力可减少同种异体移植排斥反应(AR)。我们通过支气管内滴注研究了将病毒白细胞介素-10(vIL-10)基因转入大鼠肺的可行性以及所递送的vIL-10对急性肺AR的后续影响。
首先,将腺病毒β-半乳糖苷酶载体(adv-β-gal)颗粒滴注到大鼠肺气道中,并通过组织化学染色检查β-半乳糖的蛋白质合成。接下来,在高度组织不相容的大鼠肺移植模型(BN→Lew)中研究腺病毒vIL-10载体(adv-vIL-10)转染改变AR的能力。在移植前3天,用3×10⁸ pfu/0.3 mL的adv-vIL-10(vIL-10组)或adv-β-gal(对照组)转染供体左肺。移植后第6天,收获肺同种异体移植物,并进行组织学AR分级(0-4期)。还检查了几种炎症病理类别(血管周围、支气管周围或细支气管周围单核细胞浸润、水肿、血管炎、肺泡内出血和坏死),并如前所述按0-4分进行评分。
用X-gal进行组织化学染色证实adv-β-gal在肺泡上皮细胞和肺泡巨噬细胞中成功进行了转基因蛋白质合成。vIL-10组显示出AR分期改善的趋势(3.75±0.5对4.0±0),并且与对照组相比,水肿(3.5±0.6对4.0±0)、肺泡内出血(2.3±1.0对2.5±0.6)和坏死(1.5±0.5对1.75±1.3)的病理评分也降低,然而,两组之间任何病理评分的差异均未达到统计学意义。